Investing in the future through clinical trials – AstraZeneca

Written by: Christina Archer Vice President, Development Operations, Alexion, AstraZeneca Rare Disease David Carruthers Vice President, BioPharmaceuticals Clinical Operations, BioPharmaceuticals R&D, AstraZeneca Michele Sample Vice President, Late-Stage Oncology, Clinical Operations, Oncology R&D, AstraZeneca Cristian Massacesi Chief Medical Officer, Oncology Chief Development Officer, Oncology R&D, AstraZeneca Clinical trials are foundational to the development of new medicines. From uncovering signals that may lead to potential groundbreaking therapies, to refining delivery mechanisms for treatments and identifying combination therapies, these rigorous studies drive advancements that shape healthcare. Every treatment breakthrough we rely on—from diabetes management to cancer therapies—has its roots in a clinical trial. And beyond their imperative role in determining the safety profile and efficacy of medicines, clinical trials may hold immense potential for individuals, offering hope and the prospect of new therapeutic options that can deliver better, more equitable health outcomes. At AstraZeneca, we harness this potential through a commitment to innovation and investment in our clinical trials. Clinical trials as a form of healthcare Though clinical trials are fundamental for medical advancement, their impact transcends scientific research. At their core, they represent hope, especially for people with conditions that have limited or even no treatment options. Clinical trial participants often receive
Read More